Alnylam identifies who's getting ax

Alnylam Pharmaceuticals ($ALNY) has detailed plans for laying off 52 workers, part of a broad effort to slash its RNA workforce 33%. The Boston Business Journal reports that the biotech told state officials it is axing its senior director of biotherapeutics, a senior director of business development, a senior director of pharma operations and a senior director of information technology. The Journal reports that "nine senior scientists and 14 research associates positions will also be eliminated." Story